Attention Deficit/Hyperactivity Disorder References

REFERENCES

Ghuman JK, Arnold LE, Anthony BJ. Psychopharmacological and other treatments in preschool children with attention-deficit/hyperactivity disorder: current evidence and practice. J Child Adolesc Psychopharmacol. 2008 Oct;18(5):413-447. doi: 10.1089/cap.2008.022. PMID: 18844482
Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007 Jul;46(7):894-921. PMID: 17581453
Millichap JG. Etiologic classification of attention-deficit/hyperactivity disorder. Pediatrics. 2008 Feb;121(2):e358-e365. doi: 10.1542/peds.2007-1332. PMID: 18245408
Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011 Nov;128(5):1007-1022. doi: 10.1542/peds.2011-2654. Accessed 22 Jan 2012. PMID: 22003063
Smoot LC, Boothby LA, Gillett RC. Clinical assessment and treatment of ADHD in children. Int J Clin Pract. 2007 Oct;61(10):1730-1738. PMID: 17877659
National Collaborating Centre for Mental Health. Diagnosis and management of ADHD in children, young people and adults. Attention Deficit Hyperactivity Disorder. London: The British Psychological Society, The Royal College of Psychiatrists; 2006
MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
MedWorm http://www.medworm.com/rss/index.php/Psychiatry/172/ www.medworm.com/rss/medicalfeeds/specialities/Psychiatry-News.xml
ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Process of care supplemental appendix. http://pediatrics.aappublications.org. 2011. Accessed 22 Jan 2012.
Krull KR. Attention deficit hyperactivity disorder in children and adolescents: pharmacotherapy. UpToDate. http://www.uptodate.com. 06 Jan 2012. Accessed 22 Jan 2012.
Krull KR. Attention deficit hyperactivity disorder in children and adolescents: clinical features and evaluation. UpToDate. http://www.uptodate.com. 06 Jan 2012. Accessed 22 Jan 2012.
National Collaborating Centre for Mental Health. Attention deficit hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. CG 72. http://guidance.nice.org.uk. Sep 2008.
Krull KR. Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications. UpToDate. http://www.uptodate.com. 06 Jan 2012. Accessed 22 Jan 2012.
University of Michigan Health System. Attention-deficit hyperactivity disorder. http://ocpd.med.umich.edu. Oct 2005.
Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). CADDRA: Canadian ADHD practice guidelines. 3rd Ed. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). http://www.caddra.ca/. 2011.
Dobie C, Donald WB, Hanson M,et al; Institute for Clinical Systems Improvement. Diagnosis and management of attention deficit hyperactivity disorder in primary care for school-age children and adolescents. ICSI. https://www.icsi.org/. Mar 2012.
Cincinnati Children’s Hospital Medical Center. Evidence-based clinical practice guideline for outpatient evaluation and management of attention deficit/hyperactivity disorder. http://www.cincinnatichildrens.org. Apr 2004
Institute for Clinical Systems Improvement (ICSI). Health care guideline: diagnosis and management of attention-deficit hyperactivity disorder in primary care for school age children and adolescents. ICSI. http://www.icsi.org. Jan 2005.
Scottish Intercollegiate Guidelines Network. Management of attention deficit and hyperkinetic disorders in children and young people. SIGN. http://www.sign.ac.uk. 2009.
National Institute for Health and Care Excellence. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. NICE. http://www.nice.org.uk. Mar 2006.
American Psychiatric Association. Attention-Deficit/Hyperactivity Disorder. In: Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013:59-61.
Ministry of Health Singapore. Clinical practice guidelines attention deficit hyperactivity disorder. MOH Singapore. http://www.moh.gov.sg. 2014 Jan. Accessed 22 Sep 2015.
National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE. https://www.nice.org.uk. 14 Mar 2018. Accessed 23 Jul 2018.
Krull KR. Attention deficit hyperactivity disorder in children and adolescents: clinical features and diagnosis. UpToDate. http://www.uptodate.com. Feb 2019.
French WP. Assessment and treatment of attention-deficit/hyperactivity disorder: part 1. Pediatr Ann. 2015 Mar;44(3):114-120. doi: 10.3928/00904481-20150313-13. PMID: 25806728
Wolraich ML, Hagan JF Jr, Allan C, et al. Subcommittee on Children and Adolescents with Attention-Deficit/Hyperactive Disorder. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2019 Oct;144(4):e20192528. doi: 10.1542/peds.2019-2528. Accessed 26 Feb 2021. PMID: 31570648
Substance Abuse and Mental Health Services Administration. Impact of the DSM-IV to DSM-5 Changes on the National Survey on Drug Use and Health [Internet]. Rockville (MD): Substance Abuse and Mental Health Services Administration (US). 2016 Jun. Accessed 13 Nov 2020. PMID: 30199183
Krull KR. Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents. UpToDate. https://www.uptodate.com. 24 Feb 2020. Accessed 01 Mar 2021.
Krull KR. Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications. UpToDate. https://www.uptodate.com. 10 Mar 2020. Accessed 01 Mar 2021.
Krull KR. Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis. UpToDate. https://www.uptodate.com. 10 Oct 2019. Accessed 01 Mar 2021.
Krull KR. Attention deficit hyperactivity disorder in children and adolescents: Clinical features and diagnosis. UpToDate. https://www.uptodate.com. 27 Nov 2019. Accessed 01 Mar 2021.
Almagor D, Duncan D, Gignac M, et al. CADDRA - Canadian ADHD Resource Alliance: Canadian ADHD practice guidelines, 4.1 Edition, Toronto ON. CADDRA. https://www.caddra.ca. Jan 2020. Accessed 04 Mar 2021.

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.

NCDs in Focus Act Now! Summit 2022

16 Mar 2023

Viatris, a global healthcare company, collaborated with the Thai Hypertension Society and the Thai NCD Collaboration Group to organize the NCDs in Focus Act Now! Summit 2022 in Bangkok on October 29^th and 30^th. This summit brought together nearly 300 multidisciplinary experts from Southeast Asia and India to address the unmet needs in managing two critical noncommunicable diseases (NCDs): cardiovascular diseases (CVDs) and mental health disorders (MHDs) in the region.

The summit had several key objectives. Firstly, it highlighted the effectiveness of clinical data in addressing gaps and unmet needs in clinical practice. Secondly, it emphasized the importance of sharing expertise and best practices through a platform that can optimize patient care. Additionally, it discussed the challenges of cardiovascular disease and mental health disorder care in a post COVID-19 world, and the need to re-examine them.

The summit also offered valuable insights into policy and practice changes, as well as innovative digital solutions that can lead to better outcomes. Lastly, it emphasized the significance of gaining a deeper understanding of the gaps in the patient journey to enhance patient care further.

Overall, the NCDs in Focus Act Now! Summit 2022 was a highly informative and productive event, with experts collaborating to improve the management of CVDs and MHDs in Southeast Asia and India.